» Articles » PMID: 22132212

Humoral and Cell-mediated Immunity to Pandemic H1N1 Influenza in a Canadian Cohort One Year Post-pandemic: Implications for Vaccination

Overview
Journal PLoS One
Date 2011 Dec 2
PMID 22132212
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

We evaluated a cohort of Canadian donors for T cell and antibody responses against influenza A/California/7/2009 (pH1N1) at 8-10 months after the 2nd pandemic wave by flow cytometry and microneutralization assays. Memory CD8 T cell responses to pH1N1 were detectable in 58% (61/105) of donors. These responses were largely due to cross-reactive CD8 T cell epitopes as, for those donors tested, similar recall responses were obtained to A/California 2009 and A/PR8 1934 H1N1 Hviruses. Longitudinal analysis of a single infected individual showed only a small and transient increase in neutralizing antibody levels, but a robust CD8 T cell response that rose rapidly post symptom onset, peaking at 3 weeks, followed by a gradual decline to the baseline levels seen in a seroprevalence cohort post-pandemic. The magnitude of the influenza-specific CD8 T cell memory response at one year post-pandemic was similar in cases and controls as well as in vaccinated and unvaccinated donors, suggesting that any T cell boosting from infection was transient. Pandemic H1-specific antibodies were only detectable in approximately half of vaccinated donors. However, those who were vaccinated within a few months following infection had the highest persisting antibody titers, suggesting that vaccination shortly after influenza infection can boost or sustain antibody levels. For the most part the circulating influenza-specific T cell and serum antibody levels in the population at one year post-pandemic were not different between cases and controls, suggesting that natural infection does not lead to higher long term T cell and antibody responses in donors with pre-existing immunity to influenza. However, based on the responses of one longitudinal donor, it is possible for a small population of pre-existing cross-reactive memory CD8 T cells to expand rapidly following infection and this response may aid in viral clearance and contribute to a lessening of disease severity.

Citing Articles

Latest developments in early diagnosis and specific treatment of severe influenza infection.

Valenzuela-Sanchez F, Valenzuela-Mendez B, Rodriguez-Gutierrez J, Estella A J Intensive Med. 2024; 4(2):160-174.

PMID: 38681787 PMC: 11043645. DOI: 10.1016/j.jointm.2023.09.006.


Characterization of the Efficacy of a Split Swine Influenza A Virus Nasal Vaccine Formulated with a Nanoparticle/STING Agonist Combination Adjuvant in Conventional Pigs.

Patil V, Hernandez-Franco J, Yadagiri G, Bugybayeva D, Dolatyabi S, Feliciano-Ruiz N Vaccines (Basel). 2023; 11(11).

PMID: 38006039 PMC: 10675483. DOI: 10.3390/vaccines11111707.


Role of the Host Genetic Susceptibility to 2009 Pandemic Influenza A H1N1.

Perez-Rubio G, Ponce-Gallegos M, Dominguez-Mazzocco B, Ponce-Gallegos J, Garcia-Ramirez R, Falfan-Valencia R Viruses. 2021; 13(2).

PMID: 33671828 PMC: 7926867. DOI: 10.3390/v13020344.


Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile.

Law J, Koh W, Budylowski P, Lin J, Yue F, Abe K J Immunol. 2020; 206(1):37-50.

PMID: 33208459 PMC: 7750861. DOI: 10.4049/jimmunol.2001067.


A PBMC-Based System to Assess Human T Cell Responses to Influenza Vaccine Candidates In Vitro.

Tapia-Calle G, Born P, Koutsoumpli G, Gonzalez-Rodriguez M, Hinrichs W, Huckriede A Vaccines (Basel). 2019; 7(4).

PMID: 31766202 PMC: 6963913. DOI: 10.3390/vaccines7040181.


References
1.
Scheible K, Zhang G, Baer J, Azadniv M, Lambert K, Pryhuber G . CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine. 2011; 29(11):2159-68. PMC: 3061835. DOI: 10.1016/j.vaccine.2010.12.073. View

2.
Champagne P, Ogg G, King A, Knabenhans C, Ellefsen K, Nobile M . Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001; 410(6824):106-11. DOI: 10.1038/35065118. View

3.
Tu W, Mao H, Zheng J, Liu Y, Chiu S, Qin G . Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol. 2010; 84(13):6527-35. PMC: 2903266. DOI: 10.1128/JVI.00519-10. View

4.
Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W . Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill. 2010; 15(18). View

5.
Appay V, Dunbar P, Callan M, Klenerman P, Gillespie G, Papagno L . Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002; 8(4):379-85. DOI: 10.1038/nm0402-379. View